Allarity Therapeutics, Inc.

NasdaqCM:ALLR Stock Report

Market Cap: US$20.7m

Allarity Therapeutics Future Growth

Future criteria checks 0/6

Allarity Therapeutics's revenue and earnings are forecast to decline at 152.2% and 19.3% per annum respectively while EPS is expected to decline by 15.7% per annum.

Key information

-19.3%

Earnings growth rate

-15.71%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate-152.2%
Future return on equityn/a
Analyst coverage

Low

Last updated07 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Oct 11

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics press release (NASDAQ:ALLR): Q2 GAAP EPS of -$0.72 misses by $0.46. As of June 30, 2022, Allarity’s cash was $7.7 million, as compared to $19.6 million as of December 31, 2021 Shares +4.07%.
Seeking Alpha • Aug 23

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics press release (NASDAQ:ALLR): Q2 GAAP EPS of -$0.52 misses by $0.07. The company has incurred significant losses and has an accumulated deficit of $74.2M as of June 30, 2022. The company had no cash equivalents or restricted cash on June 30, 2022, and December 31, 2021. As of August 18, 2022, our cash is insufficient to fund our current operating plan and planned capital expenditures for the next 12 months.
Seeking Alpha • Jun 29

Allarity Therapeutics appoints interim CEO, CFO

The board of clinical-stage pharmaceutical company Allarity Therapeutics (NASDAQ:ALLR) appointed Chief Business Officer James Cullem interim CEO and Director of Financial Reporting Joan Brown interim CFO, with immediate effect. Former CEO Steve Carchedi and CFO Jens Knudsen have resigned to pursue other opportunities. A permanent CEO and CFO could be named in H1 2023. Source: Press Release

Earnings and Revenue Growth Forecasts

NasdaqCM:ALLR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-16N/A-161
12/31/20260-15N/A-161
3/31/20260-11-17-17N/A
12/31/20250-11-15-15N/A
9/30/2025N/A-15-15-15N/A
6/30/2025N/A-25-17-17N/A
3/31/2025N/A-24-19-19N/A
12/31/2024N/A-25-18-17N/A
9/30/2024N/A-19-16-16N/A
6/30/2024N/A-13-16-16N/A
3/31/2024N/A-21-11-11N/A
12/31/2023N/A-20-13-13N/A
9/30/2023N/A-22-14-14N/A
6/30/2023N/A-23-13-13N/A
3/31/2023N/A-20-14-14N/A
12/31/2022N/A-21-17-17N/A
9/30/2022N/A-35-19-19N/A
6/30/2022N/A-29-18-18N/A
3/31/2022N/A-28-18-18N/A
12/31/2021N/A-27-15-15N/A
9/30/2021-1-12-13-13N/A
6/30/2021-1-12-11-11N/A
3/31/2021N/A-7-8-8N/A
12/31/2020N/A-7-7-7N/A
9/30/20201-16-7-7N/A
6/30/20201-17-8-8N/A
3/31/20200-20-10-10N/A
12/31/20190-20N/A-11N/A
9/30/20190-11N/A-10N/A
6/30/20191-8N/A-9N/A
3/31/20191-4N/A-6N/A
12/31/20181-2N/A-4N/A
9/30/20182-1N/A-2N/A
6/30/20181-1N/A-2N/A
3/31/20182-4N/A0N/A
12/31/20171-5N/A-1N/A
9/30/20171-6N/A-3N/A
6/30/20171-6N/A-3N/A
3/31/20170-4N/A-5N/A
12/31/20160-4N/A-4N/A
9/30/20161-3N/A-4N/A
6/30/20161-2N/A-4N/A
3/31/20161-2N/A-3N/A
12/31/20150-1N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALLR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALLR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALLR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALLR's revenue is expected to decline over the next 3 years (-152.2% per year).

High Growth Revenue: ALLR's revenue is forecast to decline over the next 3 years (-152.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALLR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 01:43
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allarity Therapeutics, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Nathaniel CallowayEdison Investment Research
Aydin HuseynovLadenburg Thalmann & Company